106 related articles for article (PubMed ID: 1348393)
1. The molecular genetics of lung cancer.
Carbone DP; Minna JD
Adv Intern Med; 1992; 37():153-71. PubMed ID: 1348393
[No Abstract] [Full Text] [Related]
2. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
[TBL] [Abstract][Full Text] [Related]
3. [Molecular biology of lung cancer].
Akita H
Nihon Kokyuki Gakkai Zasshi; 2004 May; 42(5):378-86. PubMed ID: 15168453
[No Abstract] [Full Text] [Related]
4. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.
Nebert DW
Cancer Cells; 1991 Mar; 3(3):93-6. PubMed ID: 2054261
[No Abstract] [Full Text] [Related]
5. [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
Bréchot JM; Molina T; Theobald S; Depierre A; Lagrange JL; Astoul P; Baldeyrou P; Bardet E; Bazelly B; Breton JL; Douillard JY; Grivaux M; Jacoulet P; Khalil A; Lemarié E; Martinet Y; Massard G; Milleron B; Moro-Sibilot D; Paesmans M; Pujol JL; Quoix AE; Ranfaing E; Rivière A; Sancho-Garnier H; Souquet PJ; Spaeth D; Stcebner-Delbarre A;
Bull Cancer; 2002 Oct; 89(10):857-67. PubMed ID: 12441277
[TBL] [Abstract][Full Text] [Related]
6. [Molecular abnormalities in lung cancer].
Shimizu S; Mitsudomi T
Nihon Rinsho; 2002 May; 60 Suppl 5():73-7. PubMed ID: 12101773
[No Abstract] [Full Text] [Related]
7. [Genetic alterations in the genesis and development of ovarian cancer].
Okamoto A; Yokoyama S; Terashima Y
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
[TBL] [Abstract][Full Text] [Related]
8. [Genetic alteration in lung cancer].
Hashimoto T; Hayashi M; Tsuchiya E
Nihon Rinsho; 2002 May; 60 Suppl 5():78-82. PubMed ID: 12101778
[No Abstract] [Full Text] [Related]
9. The evidence for human tumor suppressor genes.
Stanbridge EJ
Princess Takamatsu Symp; 1989; 20():3-13. PubMed ID: 2577336
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
11. [Genetic abnormalities in lung cancer and their prognostic implications].
Mitsudomi T; Takahashi T
Gan To Kagaku Ryoho; 1996 Jul; 23(8):990-6. PubMed ID: 8687234
[TBL] [Abstract][Full Text] [Related]
12. Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based "enriched PCR" technique.
Behn M; Qun S; Pankow W; Havemann K; Schuermann M
Clin Cancer Res; 1998 Feb; 4(2):361-71. PubMed ID: 9516924
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
14. [Molecular diagnosis of lung carcinoma].
Noguchi M
Rinsho Byori; 1994 Apr; 42(4):355-8. PubMed ID: 8176843
[TBL] [Abstract][Full Text] [Related]
15. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
16. Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer.
Viallet J; Minna JD
Am J Respir Cell Mol Biol; 1990 Mar; 2(3):225-32. PubMed ID: 1968750
[TBL] [Abstract][Full Text] [Related]
17. [Cell cycle, tumor suppressor genes and lung cancers].
Bréchot JM
Rev Mal Respir; 1998 Sep; 15(4):461-6. PubMed ID: 9805756
[TBL] [Abstract][Full Text] [Related]
18. [Molecular genetics of ovarian cancer].
Yanaihara N; Okamoto A; Takakura S; Yamada K; Ochiai K; Tanaka T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():441-8. PubMed ID: 15535284
[No Abstract] [Full Text] [Related]
19. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
20. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
Evans WE; Relling MV
Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
